Global healthcare company Viatris Inc. recently disclosed that its pharmaceutical manufacturing facility in Nashik, India, has currently suspended production activities due to a fire incident that occurred in February this year.

The company stated that it is making every effort to advance facility restoration and safety assessments, and expects to begin phased resumption of production as early as April 2026. The suspension mainly affects specific production lines at the plant. Viatris has initiated a business continuity plan, coordinating capacity through its global supply chain network to minimize the impact on product supply. The company emphasized that it will strictly comply with local regulatory requirements and resume production in an orderly manner, ensuring safety and compliance.